ABUS

Arbutus Biopharma Corporation

3.28 USD
-0.01 (-0.30%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arbutus Biopharma Corporation stock is up 20.15% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 May’s closed higher than April. In the last 2 Unusual Options Trades, there were 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Apr 17:13 19 Apr, 2024 3.00 CALL 3989 3088
09 May 17:14 21 Jun, 2024 3.00 CALL 7500 26205

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.